deaths (OS)

hepatocell cancer (HCC) hepatocell cancer (HCC)

versus Standard of Care (SoC)
sintilimab vs. Standard of Care (SoC) 1 -

mHCC - (neo)adjuvant (NA) metastatic/advanced hepatocellular cancer (mHCC) mHCC - (neo)adjuvant (NA)

versus Standard of Care (SoC)
sintilimab vs. Standard of Care (SoC) 1 -

mHCC - 1st line (L1) metastatic/advanced hepatocellular cancer (mHCC) mHCC - 1st line (L1)

versus sorafenib
sintilimab vs. sorafenib 1 certainty unassessablestatistically conclusive-40%

mHCC - 2nd line (L2) metastatic/advanced hepatocellular cancer (mHCC) mHCC - 2nd line (L2)